# Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy

> **NCT00004853** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 34 (actual)

## Conditions studied

- Ewing's Sarcoma
- Rhabdomyosarcoma
- MPNST
- Synovial Sarcoma
- High-risk Sarcoma

## Interventions

- **BIOLOGICAL:** Filgrastim
- **BIOLOGICAL:** Filgrastim-SD/01

## Key facts

- **NCT ID:** NCT00004853
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-03-03
- **Primary completion:** 2009-05-20
- **Final completion:** 2009-05-20
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004853, "Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00004853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*